Cargando…

Harnessing machine learning for development of microbiome therapeutics

The last twenty years of seminal microbiome research has uncovered microbiota’s intrinsic relationship with human health. Studies elucidating the relationship between an unbalanced microbiome and disease are currently published daily. As such, microbiome big data have become a reality that provide a...

Descripción completa

Detalles Bibliográficos
Autores principales: McCoubrey, Laura E., Elbadawi, Moe, Orlu, Mine, Gaisford, Simon, Basit, Abdul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872042/
https://www.ncbi.nlm.nih.gov/pubmed/33522391
http://dx.doi.org/10.1080/19490976.2021.1872323
_version_ 1783649128213905408
author McCoubrey, Laura E.
Elbadawi, Moe
Orlu, Mine
Gaisford, Simon
Basit, Abdul W.
author_facet McCoubrey, Laura E.
Elbadawi, Moe
Orlu, Mine
Gaisford, Simon
Basit, Abdul W.
author_sort McCoubrey, Laura E.
collection PubMed
description The last twenty years of seminal microbiome research has uncovered microbiota’s intrinsic relationship with human health. Studies elucidating the relationship between an unbalanced microbiome and disease are currently published daily. As such, microbiome big data have become a reality that provide a mine of information for the development of new therapeutics. Machine learning (ML), a branch of artificial intelligence, offers powerful techniques for big data analysis and prediction-making, that are out of reach of human intellect alone. This review will explore how ML can be applied for the development of microbiome-targeted therapeutics. A background on ML will be given, followed by a guide on where to find reliable microbiome big data. Existing applications and opportunities will be discussed, including the use of ML to discover, design, and characterize microbiome therapeutics. The use of ML to optimize advanced processes, such as 3D printing and in silico prediction of drug-microbiome interactions, will also be highlighted. Finally, barriers to adoption of ML in academic and industrial settings will be examined, concluded by a future outlook for the field.
format Online
Article
Text
id pubmed-7872042
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78720422021-02-26 Harnessing machine learning for development of microbiome therapeutics McCoubrey, Laura E. Elbadawi, Moe Orlu, Mine Gaisford, Simon Basit, Abdul W. Gut Microbes Review The last twenty years of seminal microbiome research has uncovered microbiota’s intrinsic relationship with human health. Studies elucidating the relationship between an unbalanced microbiome and disease are currently published daily. As such, microbiome big data have become a reality that provide a mine of information for the development of new therapeutics. Machine learning (ML), a branch of artificial intelligence, offers powerful techniques for big data analysis and prediction-making, that are out of reach of human intellect alone. This review will explore how ML can be applied for the development of microbiome-targeted therapeutics. A background on ML will be given, followed by a guide on where to find reliable microbiome big data. Existing applications and opportunities will be discussed, including the use of ML to discover, design, and characterize microbiome therapeutics. The use of ML to optimize advanced processes, such as 3D printing and in silico prediction of drug-microbiome interactions, will also be highlighted. Finally, barriers to adoption of ML in academic and industrial settings will be examined, concluded by a future outlook for the field. Taylor & Francis 2021-01-30 /pmc/articles/PMC7872042/ /pubmed/33522391 http://dx.doi.org/10.1080/19490976.2021.1872323 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
McCoubrey, Laura E.
Elbadawi, Moe
Orlu, Mine
Gaisford, Simon
Basit, Abdul W.
Harnessing machine learning for development of microbiome therapeutics
title Harnessing machine learning for development of microbiome therapeutics
title_full Harnessing machine learning for development of microbiome therapeutics
title_fullStr Harnessing machine learning for development of microbiome therapeutics
title_full_unstemmed Harnessing machine learning for development of microbiome therapeutics
title_short Harnessing machine learning for development of microbiome therapeutics
title_sort harnessing machine learning for development of microbiome therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872042/
https://www.ncbi.nlm.nih.gov/pubmed/33522391
http://dx.doi.org/10.1080/19490976.2021.1872323
work_keys_str_mv AT mccoubreylaurae harnessingmachinelearningfordevelopmentofmicrobiometherapeutics
AT elbadawimoe harnessingmachinelearningfordevelopmentofmicrobiometherapeutics
AT orlumine harnessingmachinelearningfordevelopmentofmicrobiometherapeutics
AT gaisfordsimon harnessingmachinelearningfordevelopmentofmicrobiometherapeutics
AT basitabdulw harnessingmachinelearningfordevelopmentofmicrobiometherapeutics